Comprehensive Profiling
Covers 1021 genes and 16,000 SNP sites for variant detection and TMB, MSI, and HRD assessment.
OncoOmni
OncoOmni
OncoOmni is a hybrid capture-based NGS assay integrating 1021-gene profiling and homologous recombination deficiency (HRD) assessment for FFPE solid-tumor samples. It profiles SNVs, InDels, CNVs, and fusions/rearrangements, alongside TMB, MSI, and HRD status. Paired with the Gene⁺GIN16 Automated Workstation, it automates library preparation and hybrid capture for up to 16 samples per run.
*For Research Use Only.
Absolute Copy Number Estimation
Estimates absolute gene copy number in tumor cells and detects homozygous deletions, including MTAP.
Automated Workflow
Fully automates library preparation and hybrid capture on the Gene⁺GIN16 workstation.
Robust Performance
Approximately 95% testing success rate. *Based on internal testing data from the GenePlus Central Laboratory.